During sepsis endothelial dysfunction is an important pathogenetic mechanism in acute kidney injury (AKI). Lipopolysaccharide (LPS)-induced endotoxemia is associated with renal hemodynamic changes such as alterations of renal blood flow (RBF), vascular resistance, and glomerular filtration rate. We used adenoviral delivery of an engineered variant of native angiopoietin-1 (COMP-angiopoietin-1) containing anti-inflammatory and anti-permeability functions, to determine if regulation of renal endothelial cell dysfunction may have a beneficial role in preventing AKI during LPS-induced endotoxemia in mice. This treatment prevented the endotoxin-induced decrease of RBF and mean arterial pressure while improving glomerular filtration rate. Treatment also mitigated the effects of LPS on renal intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 protein expression, the number of ER-HR3positive macrophages that infiltrated the kidney, serum nitrate/nitrite levels, renal inducible nitric oxide synthase protein expression, the induction of tubular epithelial reactive oxygen and nitrogen species, and renal microvascular permeability. Our findings show that COMP-angiopoietin-1, an endothelium-oriented therapeutic agent, protects against AKI caused by endotoxemia.
During sepsis endothelial dysfunction is an important pathogenetic mechanism in acute kidney injury (AKI). Lipopolysaccharide (LPS)-induced endotoxemia is associated with renal hemodynamic changes such as alterations of renal blood flow (RBF), vascular resistance, and glomerular filtration rate. We used adenoviral delivery of an engineered variant of native angiopoietin-1 (COMP-angiopoietin-1) containing anti-inflammatory and anti-permeability functions, to determine if regulation of renal endothelial cell dysfunction may have a beneficial role in preventing AKI during LPS-induced endotoxemia in mice. This treatment prevented the endotoxin-induced decrease of RBF and mean arterial pressure while improving glomerular filtration rate. Treatment also mitigated the effects of LPS on renal intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 protein expression, the number of ER-HR3positive macrophages that infiltrated the kidney, serum nitrate/nitrite levels, renal inducible nitric oxide synthase protein expression, the induction of tubular epithelial reactive oxygen and nitrogen species, and renal microvascular permeability. Our findings show that COMP-angiopoietin-1, an endothelium-oriented therapeutic agent, protects against AKI caused by endotoxemia. Sepsis is a systemic inflammatory response to infection and is associated with the production of nitric oxide (NO), platelet activation factor, and eicosanoids. Sepsis has been implicated in endothelial cell dysfunction, increased permeability, hypotension, inadequate organ perfusion, and cell death associated with multiple organ failure. 1 Acute kidney injury (AKI) occurs in about half of the patients in septic shock, and mortality from septic AKI is extremely high. 2 Endotoxins produced by bacteria, such as lipopolysaccharide (LPS), are associated with renal hemodynamic changes such as alteration of renal blood flow (RBF), renal vascular resistance, and glomerular filtration rate. 3, 4 Renal microvascular injury is a major mechanism of AKI, and peritubular capillary dysfunction in endotoxemia contributes to LPS-induced renal injury. 3, [5] [6] [7] [8] Thus, peritubular endothelial dysfunction is an important pathogenetic mechanism in AKI in sepsis.
Another hallmark of vascular dysfunction in sepsis is hyperpermeability secondary to microcirculatory/capillary leakage. 9 The presence of profound vascular leakage with the movement of fluid and macromolecules into the renal interstitium is an essential feature of AKI in sepsis, and changes in vascular endothelial integrity with increased permeability contribute to the development of renal failure. Therefore, an endothelial-specific modality to normalize renal hemodynamics, inflammation, and renal vascular permeability may decrease AKI in sepsis and subsequently improve the mortality rate in septic patients.
Angiopoietin-1 (Ang1) is an angiogenic factor essential to embryonic vascular development through its actions on an endothelial receptor tyrosine kinase. 10, 11 Ang1 also decreases vascular permeability 12 and has anti-inflammatory 13 and anti-apoptotic 14 properties. Ang1 improves hemodynamic function, reduces lung injury, lowers expression of inflammatory adhesion molecules, and preserves endothelial nitric oxide synthase (eNOS) activity in the lung tissue in an LPSinduced endotoxic shock model. 15, 16 COMP-Ang1, a variant of native Ang1 engineered by replacing the N-terminus of Ang1 with cartilage oligomeric matrix protein (COMP), is more potent than native Ang1 in phosphorylating Tie2 and signaling through Akt in primary cultured endothelial cells. 17 Recently, we have demonstrated that treatment with COMP-Ang1 decreases the progression of renal fibrosis in a unilateral ureteral obstruction model. Thus, COMP-Ang1 may have potential as an endothelium-oriented therapeutic agent in chronic renal disease. 18 However, there have been no reports about the possible effects of COMP-Ang1 on septic AKI.
In this study, we examined whether COMP-Ang1 has renoprotective effects using a murine model of AKI. Our results demonstrated that COMP-Ang1 treatment improves renal function by regulating renal hemodynamics, preserving renal endothelial cells integrity, decreasing expression of intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) and macrophage infiltration, ameliorating serum NO levels and inducible nitric oxide synthase (iNOS) expression, suppressing renal reactive oxygen species (ROS) and reactive nitrogen species (RNS), and decreasing LPS-induced increased renal vascular permeability in a mouse model of LPS-induced endotoxemic AKI.
RESULTS

Effect of COMP-Ang1 on renal hemodynamics and renal function during endotoxemia
Treatment of mice with LPS significantly decreased mean arterial pressure (MAP) compared with vehicle alone. Pretreatment with COMP-Ang1 adenovirus attenuated the LPS-induced decrease of MAP ( Figure 1a ). RBF was significantly lower in mice treated with LPS than that in mice treated with vehicle, but COMP-Ang1 prevented much of the LPS-induced lowering of RBF ( Figure 1b ). The calculated renal vascular resistance (MAP/RBF) was significantly lower in the group treated with COMP-Ang1 and LPS than in the group treated with LPS only (Figure 1c ). Treatment with COMP-Ang1 alone did not alter MAP, RBF, or renal vascular resistance, producing similar results to treatment with vehicle alone (Figure 1a -c). Our data showed that serum creatinine tended to increase after treatment with LPS than after treatment with control buffer. However, this did not reach statistical significance (0.35 ± 0.07 mg/dl in control buffer-treated mice, 0.53 ± 0.12 mg/dl in LPS-treated mice, n ¼ 4 in each group). Blood urea nitrogen levels after treatment with LPS were significantly higher than after treatment with control buffer (22.5±9.1 mg/dl in control buffer-treated mice, 81.4±24.7 mg/dl in LPS-treated mice, n ¼ 4 in each group, Po0.05). Treatment with COMP-Ang1 did not significantly decrease the LPS-induced increase of blood urea nitrogen (81.4 ± 24.7 mg/dl in LPS-treated mice, 80.0 ± 17.6 mg/dl in LPS plus COMP-Ang1-treated mice, n ¼ 4 in each group). As chromagens in mouse serum may affect the serum creatinine levels when the picric acid method is used for measurement and as inulin clearance has been considered as the gold-standard method for measuring glomerular filtration rate, we also measured glomerular filtration rate by inulin clearance. The inulin clearance of mice treated with LPS was significantly lower than that in mice treated with vehicle or COMP-Ang1 alone. COMP-Ang1 significantly attenuated the LPS-induced decrease in the inulin clearance ( Figure 1d ). The inulin clearance of the mice treated with COMP-Ang1 alone did not differ from that of mice treated with vehicle alone. These data suggest that COMP-Ang1 improves renal hemodynamics and the glomerular filtration rate in endotoxemic mice.
COMP-Ang1 ameliorates LPS-induced renal endothelial injury
PECAM-1 and vWF are markers of endothelial cell and Ang1 is an antiapoptotic factor in endothelial cells. [18] [19] [20] We evaluated whether pretreatment with COMP-Ang1 preserves renal PECAM-1-positive peritubular capillary endothelial cells in mice with LPS-induced endotoxemia. COMP-Ang1 reduced the LPS-induced decrease of PECAM-1-positive endothelial cells (Figure 2a-d ). Immunohistochemical analyses of kidneys showed that also induction of endotoxemia with LPS significantly decreased the area densities of vWFpositive cells compared with those of vehicle or COMP-Ang1 alone. The addition of COMP-Ang1 to the LPS treatment prevented much of the decrease in the density of vWF immunoreactivity that was induced by treatment with LPS only (Figure 2e ). To evaluate the antiapoptotic effect of COMP-Ang1 in LPS-treated renal endothelial cells, we stained kidney sections for PECAM-1 and TUNEL. The number of cells in the kidney positive for both PECAM-1 and TUNEL was higher after 12 h treatment with LPS than after treatment with control buffer. COMP-Ang1 decreased the LPS-induced increase in the number of PECAM-1-and TUNEL-positive cells in the kidney (Figure 2f -j). Electron microscopy of peritubular endothelial cells in mice treated with vehicle alone showed normal cellular architecture. In contrast, an ultrastructural analysis of peritubular endothelial cells in LPS-treated mice showed severe subcellular injuries. Endothelial cells were detached from the basement membrane, and the plasma membrane was destroyed. Treatment with COMP-Ang1 prevented the LPS-induced destruction of the endothelial cell integrity. The junction of the endothelial cells and basement membrane was well preserved, and the plasma membrane and the intracellular organelles were also relatively well preserved (Figure 2k -m). These results indicate that COMP-Ang1 preserves the integrity of renal endothelial cells in endotoxemic mice.
COMP-Ang1 decreases LPS-induced renal ICAM-1 and VCAM-1 protein expression
Lipopolysaccharide induces vascular inflammation and compromises vascular function; renal interstitial ICAM-1 and VCAM-1 protein expression may therefore be associated with LPS-induced renal injury. 21 Immunoblot analyses were used to evaluate the changes in ICAM-1 and VCAM-1 expression in the kidneys. The expression of ICAM-1 was about sevenfold higher in kidneys from LPS-treated mice than in kidneys from the control mice treated with vehicle alone. The administration of COMP-Ang1 adenovirus inhibited the LPS-induced increase in ICAM-1 protein expression by about 65% (Figure 3a) . LPS significantly increased renal VCAM-1 protein expression to about 3.2-fold the expression level after vehicle treatment. The increase in the renal VCAM-1 protein level after treatment with COMP-Ang1 and LPS was about 53% of the increase after LPS alone ( Figure 3b ). However, COMP-Ang1 alone did not change renal ICAM-1 or VCAM-1 protein expression.
COMP-Ang1 suppresses LPS-induced ICAM-1 expression and ER-HR3-positive macrophage infiltration in the renal interstitial space
We performed immunohistochemical studies to localize ICAM-1 expression and to evaluate changes in the number of ER-HR3positive macrophages in endotoxemic mice. ICAM-1 was upregulated throughout the renal interstitial space after LPS treatment (Figure 3e and g). Pretreatment with COMP-Ang1 adenovirus significantly decreased the LPS-induced expression of interstitial ICAM-1 (Figure 3f and g). LPS treatment increased the infiltration of ER-HR3-positive macrophages into the kidney by sevenfold over than that in the kidney from mice treated with vehicle alone (Figure 4 ). Pretreatment with COMP-Ang1 decreased the LPS-induced accumulation of ER-HR3-positive macrophages in kidney by about 60%, whereas COMP-Ang1 alone had no effect ( Figure 4 ).
COMP-Ang1 protein treatment after LPS injection also suppresses LPS-induced ICAM-1 expression and ER-HR3-positive macrophage infiltration in the kidney
We administered COMP-Ang1 protein (200 mg) just after LPS injection and evaluated the changes of ICAM-1 expression and the number of ERHR-3-positive macrophages in kidney after 16 h. Treatment with COMP-Ang1 protein after LPS injection also significantly decreased the LPS-induced ICAM-1 protein expression and the number of LPS-induced ERHR-3-positive macrophages in kidney ( Supplementary  Figure 1 ).
COMP-Ang1 decreases serum nitrate/nitrite levels and renal iNOS protein expression in LPS-induced AKI
As renal hemodynamic changes are strongly influenced by the production of NO in endotoxemic mice, and serum nitrate and nitrite are markers of NO generation in vivo. 22 we evaluated the effect of COMP-Ang1 adenovirus on serum levels of nitrate and nitrite in LPS-induced AKI. LPS induced about a 14-fold rise in serum nitrate and nitrite levels compared with the levels in the serum from the control mice treated with vehicle alone. Nitrate and nitrite levels in mice treated with LPS and COMP-Ang1 were 33% lower than in mice treated with LPS alone (Figure 5a ). COMP-Ang1 alone did not alter the levels of serum nitrate and nitrite showing that COMP-Ang1 itself did not affect NO generation.
Induction of iNOS protein expression in the kidney is accompanied by a significant increase in serum NO levels. 23, 24 To ascertain the above findings, we also investigated the effect of COMP-Ang1 on renal iNOS protein expression in LPS-induced AKI. Administration of LPS resulted in an approximately 13-fold increase in renal iNOS protein expression over the expression in mice treated with vehicle or COMP-Ang1 alone. Pretreatment with COMP-Ang1 suppressed the LPS-induced increase in iNOS expression by about 80% (Figure 5b ). Thus, COMP-Ang1 attenuated the induction of iNOS expression as well as serum NO levels in LPS-induced AKI.
COMP-Ang1 decreases renal vascular permeability and increases renal tissue blood flow
As endotoxin-induced AKI is associated with increased microvascular leakage in the kidney, we examined the effect of COMP-Ang1 adenovirus on the kidney vasculature in LPS-induced AKI by measuring the leakage of Evans blue dye. 25 Treatment with LPS increased renal vascular permeability compared with treatment with vehicle or COMP-Ang1 alone. Pretreatment with COMP-Ang1 significantly prevented the LPS-induced increase in renal vascular permeability ( Figure 6a ). The renal vascular permeability was similar in mice treated with vehicle alone and COMP-Ang1 alone.
In addition, influence of COMP-Ang1 adenovirus on renal cortical and medullary blood flow was also measured by a laser-Doppler flow ultrasonography. Treatment with LPS decreased renal cortical and medullary blood flow by about 73.2 and 76.0%, respectively, compared with vehicle alone. After LPS with COMP-Ang1 treatment, renal cortical and medullary blood flow were about 2.7-fold and 2.3-fold higher, respectively, than after LPS treatment alone ( Figure 6b ). However, COMP-Ang1 alone had no effect on the cortical or medullary blood flow.
COMP-Ang1 suppresses renal tubular ROS/RNS production in endotoxemic mice
Dihydrorhodamine-123 (DHR) is oxidized to fluorescent rhodamine by hydroxyl radicals, nitrogen dioxide, peroxynitrite, and peroxidase-derived species, which are ROS or RNS. 26 Thus, the oxidation of DHR to rhodamine can be used as an indicator of ROS/RNS generation. Wu et al. 3, 27 demonstrated that renal peritubular capillary dysfunction with reduced perfusion increases rhodamine fluorescence in renal tubular epithelial cells and induces AKI in the cecal-ligationand-puncture murine model of sepsis. We demonstrated that COMP-Ang1 adenovirus improved renal cortical and medullary blood flow in mice with LPS-induced endotoxemia ( Figure 6b ). Therefore, we used DHR with laser scanning confocal microscopy and intravital microscopy to evaluate whether COMP-Ang1 treatment can decrease renal epithelial ROS/RNS generation in LPS-induced kidney injury. Confocal microscopic images showed an increased rhodamine fluorescence in the renal epithelial cells of mice treated with LPS compared with that in the renal epithelial cells from mice treated with vehicle or COMP-Ang1 alone. Pretreatment with COMP-Ang1 decreased the LPS-induced intensity of rhodamine fluorescence in the renal tubular epithelial cells (Figure 7) .
Representative intravital microscopic images of rhodamine fluorescence from the kidney of mice after LPS treatment are shown in Figure 8 and Supplementary video clips. The intensity of rhodamine fluorescence was markedly increased in tubular epithelial cells by the LPS treatment (Figure 8c and Supplementary Video Clips 1 and 3) . Pretreatment with COMP-Ang1 reduced the increase in LPS-induced rhodamine fluorescence (Figure 8d and Supplementary Video clip 4). COMP-Ang1 alone had no significant effect on ROS/RNS generation (Figure 8b and Supplementary Video clip 2). These results suggest that COMP-Ang1 decreases LPS-induced ROS/RNS production in the renal tubular cells of endotoxemic mice.
COMP-Ang1 increases renal Akt phosphorylation through Tie2 in endotoxemic mice
Phosphorylation of Akt in endothelial cells is an important downstream pathway of COMP-Ang1. 19 COMP-Ang1 increased renal Akt phosphorylation 16 h after LPS injection compared with the levels in mice treated with control buffer. The mean increases in Akt phosphorylation after treatment with COMP-Ang1 were 2.2-fold at 16 h (Figure 9 ). Injection of LPS itself did not significantly activate phosphorylation of Akt in kidney. Treatment with COMP-Ang1 itself increased phosphorylation of Akt in kidney. To determine the involvement of Tie2 in COMP-Ang1-induced Akt phosphorylation in LPS-treated kidney, mice were pretreated with sTie2-Fc 24 h before the COMP-Ang1 treatment. Pretreatment with sTie2-Fc prevented the COMP-Ang1-induced Akt phosphorylation, indicating that COMP-Ang1-induced Akt phosphorylation occurs primarily through Tie2 in the kidney (Figure 9 ).
DISCUSSION
Clinical and experimental studies have indicated that changes in renal hemodynamics may have a critical role in AKI. [28] [29] [30] LPS induces renal hemodynamic changes including RBF and glomerular filtration rate. Decreased peritubular capillary perfusion has also been associated with renal injury in a murine model of LPS-induced endotoxemia. 3 Thus, preservation of renal hemodynamics with maintenance of peritubular capillary perfusion may protect against AKI in models of sepsis.
Recent studies have suggested that Ang1 exhibits protective effects against endotoxemia, increasing vasoconstriction 31 and reducing pulmonary microvascular leakage associated with inflammation. 15 It has been reported that circulating Ang1 levels were suppressed in critically ill patients with septic shock. 32 Schabbauer et al. 33 have demonstrated that inhibition of the phosphoinositide 3-kinase-Akt pathway enhanced LPS-induced endothelial E-selectin expression and they have also suggested that this pathway suppresses LPS-induced inflammation in endotoxemic mice. Thus, Ang1, which phosphorylates the phosphoinositide 3-kinase-Akt pathway in endothelial cell, has the potential to increase vascular reactivity and decrease inflammation in endotoxemia.
In our experiment, treatment with LPS tended to increase serum creatinine more than treatment with control buffer, but this difference did not reach statistical significance. Interference by serum chromagens of the serum creatinine measurement and the high standard deviation might have contributed to this lack of statistical significance. Blood urea nitrogen levels were significantly higher after treatment with LPS than after treatment with control buffer; however, COMP-Ang1 did not significantly decrease blood urea nitrogen from the levels seen after treatment with LPS. As chromagens in mouse serum may affect the serum creatinine levels when the picric acid method is used for measurement , and LPS plus COMP-Ang1 (j-l) were harvested 15 min after the DHR injection. Note that the intensity of rhodamine was increased in renal tubular epithelial cells (g; arrow and inset), and this increased intensity was lower in the LPS plus COMP-Ang1 group than in the LPS plus vehicle group, n ¼ 3 for each experimental group. Scale bar ¼ 50 mm. and as inulin clearance has been considered as the goldstandard method for measuring the glomerular filtration rate, we also measured the inulin clearance.
Interactions between leukocytes and adhesion molecules on endothelial cells can be an important mechanism of LPSinduced inflammation. The increased expression of ICAM-1 represents an early inflammatory response to LPS and suggests that endothelial inflammation may propagate inflammatory cell infiltration, leading ultimately to renal injury. Macrophages have been implicated in the pathogenesis of AKI. 34 Therefore, downregulation of ICAM-1 expression decreases the infiltration of inflammatory cells into the kidney. Thus, in this experiment we evaluated ICAM-1 expression in kidney 12 h after LPS injection and changes in the number of ERHR-3-positive macrophages in kidney 5 days after LPS injection. Our data demonstrated that treatment with COMP-Ang1 decreased LPS-induced ICAM-1 expression and ERHR-3-positive macrophage infiltration in the kidney.
However, the role of COMP-Ang1, a variant of Ang1, in AKI has not been examined. Our results revealed that COMP-Ang1 attenuates LPS-induced renal dysfunction by regulating renal hemodynamics, preserving renal endothelial cells, and decreasing ICAM-1 and VCAM-1 protein expression and macrophage infiltration in a model of endotoxemic AKI.
Recently, Long et al. 35 have reported that Ang1 has profibrotic and inflammatory effects in folic acid-induced acute renal injury. However, our data demonstrated that COMP-Ang1 suppressed ICAM-1 and VCAM-1 protein expression and macrophage infiltration in LPS-induced endotoxemic AKI. It has been found that dose and the form of Ang1 may have an important role in outcome. 35 Thus, these findings suggest that the anti-inflammatory effect of Ang1 may be different according to the kidney disease model.
Renal hemodynamic is dramatically changed after LPS injection. LPS-induced renal hemodynamic changes are associated with dysfunction of the renal vasculature. Thus, measurement of renal hemodynamic parameters, such as renal arterial blood flow and blood flow in cortex and medulla, are important in LPS-induced AKI. Data about RBF reflect the renal hemodynamics associated with systemic circulation and data about blood flow in the cortex and medulla reflect the renal hemodynamics in the microcirculation. In this experiment, our data demonstrated that COMP-Ang1 ameliorated the LPS-induced decrease of RBF in the renal artery and in cortex and medulla of the renal tissue.
Wu et al. 27 have demonstrated that decreased peritubular capillary perfusion increases ROS/RNS production in epithelial cells and subsequently increases tubular cell injury. They suggest that ROS/RNS in epithelial cells should be considered as potential therapeutic targets for the treatment of sepsisinduced AKI. We demonstrated that COMP-Ang1 ameliorates LPS-induced endothelial dysfunction and attenuates the LPS-induced decrease of renal cortical and medullary blood flow ( Figure 6 ). Our data also demonstrated that treatment with COMP-Ang1 decreases the LPS-induced production of ROS/RNS in renal tubular epithelial cells. Therefore, as COMP-Ang1 acts on the renal endothelial Tie2 receptor, our data suggest that COMP-Ang1 suppresses LPS-induced RNS/ ROS production in renal tubular epithelial cells through actions on renal endothelial cells. A major limitation of this experiment is that pretreatment is necessary because adenovirus is used as a delivery vehicle. Systemic administration of conventional adenovirus can lead to the accumulation of virus particles in the liver, which may cause liver injury. Therefore, the systemic administration of COMP-Ang1 using adenovirus may have limited clinical applicability. For this reason, a novel adenovirus with minimal hepatic dysfunction or lipid formulations such as liposomes and micellar solutions will be needed for the development of clinical applications of COMP-Ang1, as it will take about 3 days to reach the peak concentration of COMP-Ang1.
The alterations in glomerular filtration rate and RBF in our experiment could cause problems in probe delivery and clearance from the kidneys, especially in the immunofluorescence staining and inulin-fluorescein isothiocyanate (FITC) experiments. We used a control antibody in the immunofluorescence staining experiment and found that there was no significant signal from kidney section.
COMP-Ang1 protects against LPS-induced AKI by significantly improving renal hemodynamics, iNOS-induced NO production, ICAM-1 and VCAM-1 protein expression, renal tissue blood flow, and epithelial ROS/RNS production in endotoxemic mice. COMP-Ang1 may therefore be a novel, endothelium-targeted therapy for preventing LPS-induced AKI in sepsis.
MATERIALS AND METHODS
Animal experiments C57BL/6 mice (Charles River Korea, Seoul, Korea; 20-30 g body weight) were used in these experiments. All animal studies were reviewed and approved by the Institutional Animal Care and Use Committee of Chonbuk National University. Recombinant adenoviruses expressing COMP-Ang1 or LacZ were constructed using previously published methods. 17 For adenoviral treatment, Ade-COMP-Ang1 or Ade-LacZ (vehicle) diluted in 50 ml of sterile 0.9% NaCl was injected intravenously (i.v.) through the tail vein. In our previous experiments, circulating serum levels of COMP-Ang1 increased 3 days after treatment, peaked at 5 days, and declined thereafter. 18 To evaluate the effect of high levels of COMP-Ang1 in the endotoxemic model, mice received an i.v. injection of COMP-Ang1 adenovirus or vehicle adenovirus 3 days before LPS injection. At 16 h after the injection of LPS (8 mg/kg) or control buffer, mice were anesthetized with ketamine (100 mg/kg) and xylazine (10 mg/kg), and subsequently killed by cervical dislocation. Kidneys were harvested for immunoblotting and immunohistochemistry. To determine the effects of COMP-Ang1 on ER-HR3-positive macrophage cell infiltration in kidneys, the kidneys were used for ER-HR3 immunohistochemistry 5 days after the injection of LPS or control buffer. To evaluate the effect of administering COMP-Ang1 protein after LPS injection, we treated mice with COMP-Ang1 protein (200 mg) just after LPS injection and evaluated the changes of ICAM-1 expression in kidney 16 h after COMP-Ang1 protein injection and the number of ERHR-3-positive macrophage in kidney 5 days after COMP-Ang1 protein injection.
Measurement of MAP, RBF, and glomerular filtration rate Measurements of MAP were performed as described previously. 36 COMP-Ang1 or vehicle was injected 3 days before LPS (8 mg/kg, i.p.) or control buffer injection (n ¼ 8 in each group). Sixteen hours after LPS or control buffer injection, the animals were anesthetized with ketamine (100 mg/kg) and xylazine (10 mg/kg) and placed on a thermostatically controlled surgical table. Cannulas (PE10) were placed into the carotid artery to measure systemic MAP and in the jugular vein for maintenance infusions. The MAP cannula was connected to a pressure transducer (MLT1050/A Precision BP transducer, ADInstruments, Castle Hill, Australia) and monitored continuously using a PowerLab System (ADInstruments). Measurements of RBF were performed as described previously. 19 After the mouse was placed on its right side, the left kidney was exposed through a subcostal incision. The left renal arteries were isolated for the determination of RBF using a blood flowmeter and probe (0.5-mm, Type V; Transonic Systems, Ithaca, NY, USA). An intravenous maintenance infusion of 2.25% bovine serum albumin in normal saline was injected at 0.25 ml/g body weight/min during the measurement. Determination of glomerular filtration rate was performed with FITC-inulin as described previously. 37 Sixteen hours after LPS or control buffer injection (n ¼ 10 in each group), an intravenous maintenance infusion of 2.25% bovine serum albumin in normal saline at a rate of 0.25 ml/g body weight/min was started 1 h before experimentation; 0.75% FITC-inulin was added to the infusion solution for the determination of glomerular filtration rate as described previously. 2 A bladder catheter (PE10) was used to collect urine. Two 30-min collections of urine were obtained and weighed to determine the volume. Blood for plasma inulin determination was drawn between urine collections. FITC in plasma and urine samples were measured using a SpectraMax Gemini fluorescence plate reader (Molecular Devices, Sunnyvale, CA, USA).
Immunohistochemistry and immunofluorescence double staining
Immunohistochemical analyses were performed as previously described. 20, 38 The kidney blocks were sectioned at 5 mm and stained with rabbit antihuman vWF (Chemicon International, Temecula, CA, USA), ICAM-1 (BD Pharmingen, San Diego, CA, USA) antibodies. For immunofluorescence staining, fresh-frozen renal tissue was incubated with anti-PECAM-1 (Chemicon International) or ER-HR3 (BMA Biomedical, Augst, Switzerland) and a Cy3-labeled secondary antibody. Kidney tissues were incubated with the TUNEL reaction mixture (Roche Applied Science, Indianapolis, IN, USA) containing terminal deoxynucleotidyl transferase and nucleotides including FITC-labeled dUTP. Ten digital images of every other nonoverlapping Â 400 microscopic field across the renal cortex and medulla were captured with a Zeiss Z1 microscope (Carl Zeiss, Göttingen, Germany). The area positive for vWF or ICAM-1 was evaluated from the unit area ( Â 400 magnification field) and expressed as a percentage per unit area using a digital image analysis program (AnalySIS, Soft Imaging System, Münster, Germany). 39 Immunoblotting Immunoblotting was performed as previously described. 40 Serum nitrate/nitrite levels Blood samples were taken from mice 16 h after the administration of LPS (8 mg/kg) or control buffer (n ¼ 4 in each group). Serum nitrate/nitrite levels were determined by using a commercial kit (Nitrate/Nitrite Colorimetric Assay Kit, Cayman Chemical Company, Ann Arbor, MI) according to the manufacturer's instructions. Absorbance was read at 540 nm using a THERMOmax microplate reader (Molecular Devices).
Vascular permeability measurement using Evans blue dye
The microvascular leakage of Evans blue dye was assessed as described previously. 9 Thirty minutes before killing, the mice were anesthetized with ketamine (100 mg/kg) and xylazine (10 mg/kg) and injected i.v. with 2 ml Evans blue dye (1% in 0.9% NaCl solution) per kilogram body weight through the tail vein. At killing, the mice were perfused with normal saline through the left ventricle until all blood was eliminated. The kidneys were excised, decapsulated, dried by centrifugation at 25 1C under vacuum, and weighed to estimate the dry weight. The kidneys were homogenized in 1 ml of formamide, incubated at 55 1C for 18 h, and then centrifuged at 16,000 g for 30 min at 4 1C The amount of Evans blue in the supernatant was determined by measuring absorbance at 620 nm with a SmartSpec Plus spectrophotometer (BioRad, Hercules, CA, USA) and correcting for the extraction volume.
Transmission electron microscopy
Electron microscopy was performed as previously described. 41 Ultrathin sections cut on an ultramicrotome (ULTRACUTE, Leica Microsystems, Wetzlar, Germany) were counterstained with uranyl acetate and lead citrate and examined in electron microscope (JEM-1200EXII, JEOL, Tokyo, Japan).
Measurement of renal cortical and medullary blood flow
Changes in the blood flow in the superficial renal cortex and medulla were measured using a laser-Doppler flow probe (1.2-mm diameter, Type N; Transonic Systems), as described previously. 18 
Evaluation of ROS/RNS generation ex vivo and in vivo
To evaluate ROS/RNS generation in the kidney, we used a confocal laser scanning microscope. At 16 h after the injection of LPS, 3 mg/ kg DHR (Invitrogen, Eugene, OR) was administered i.v. After 15 min, mice were anesthetized and subsequently killed by cervical dislocation. Frozen sections of kidney were prepared for confocal laser scanning imaging of DHR obtained with an LSM 510 META confocal laser scanning microscope (Carl Zeiss). We used the intravital microscope as previously described. 18 In brief, 16 h after injection of LPS, DHR (0.3 mg/kg) was administered i.v. 15 min before examination. Kidneys were exposed by retroperitoneal incision and episcopically illuminated (excitation ¼ 535 nm, emission ¼ 590 nm) under a fluorescence intravital microscope. Realtime imaging was recorded at 30 frames/s using a Cascade 650 CCD camera (Roper Scientific, Tucson, AZ) and MetaMorph software (Universal Imaging, Sunnyvale, CA, USA). Six randomly selected regions (250 Â 180 mm 2 ) were evaluated at each time point.
Statistical analysis
Data are expressed as means±s.d. Student's t-test was used to compare the means of normally distributed continuous variables. Multiple comparisons were examined for significant differences using analysis of variance, followed by individual comparisons with the Tukey post hoc test. Statistical significance was set at Po0.05.
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